Initially, we aimed to assess the relevance of SHMT2 as a potential therapeutic target in lung cancer by evaluating its expression levels in healthy individuals and patients diagnosed with lung adenocarcinoma (LUAD). The gene discussed is SHMT2; the disease is lung adenocarcinoma.